Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Alice Mogenet, Laurent Greillier & Pascale Tomasini. (2021) The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. Pharmacogenomics and Personalized Medicine 14, pages 987-996.
Read now
Read now
Miaomiao Wen, Jinghua Xia, Ying Sun, Xuejiao Wang, Xianghui Fu, Yanning Zhang, Zhipei Zhang, Yongan Zhou & Xiaofei Li. (2018) Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. Biologics: Targets and Therapy 12, pages 183-190.
Read now
Read now
Rumiko Shimazawa & Masayuki Ikeda. (2016) Drug–diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics 16:2, pages 187-204.
Read now
Read now
Mauricio Burotto, Syed Abbas Ali & Geraldine O’Sullivan Coyne. (2015) Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Expert Opinion on Drug Safety 14:1, pages 97-110.
Read now
Read now
Patricia M LoRusso & Joseph Paul Eder. (2008) Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opinion on Investigational Drugs 17:7, pages 1013-1028.
Read now
Read now
Alex Y Chang. (2008) The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs 17:3, pages 401-411.
Read now
Read now
Articles from other publishers (68)
Chuan-Hsin Chang & Yue-Cune Chang. (2022) Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. International Journal of Environmental Research and Public Health 19:21, pages 14324.
Crossref
Crossref
Chee-Hong Takahiro Yew, Narmatha Gurumoorthy, Fazlina Nordin, Gee Jun Tye, Wan Safwani Wan Kamarul Zaman, Jun Jie Tan & Min Hwei Ng. (2022) Integrase deficient lentiviral vector: prospects for safe clinical applications. PeerJ 10, pages e13704.
Crossref
Crossref
Javier Peinado-Serrano & Amancio Carnero. (2022) Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers 14:9, pages 2202.
Crossref
Crossref
Begoña Campos‐Balea, Javier Castro Carpeño, Bartomeu Massutí, David Vicente‐Baz, Diego Pérez Parente, Pedro Ruiz‐Gracia, Leonardo Crama & Manuel Cobo Dols. (2020) Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. Thoracic Cancer 11:11, pages 3357-3364.
Crossref
Crossref
Yang-Gun Suh & Jaeho Cho. (2019) Local ablative radiotherapy for oligometastatic non-small cell lung cancer. Radiation Oncology Journal 37:3, pages 149-155.
Crossref
Crossref
Yanqing Chen, Yang Yang, Longbai Ma, Huiyuan Zhu, Tienan Feng, Sen Jiang, Youyong Wei, Tingting Wang & Xiwen Sun. (2019) Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma. European Journal of Radiology 112, pages 44-51.
Crossref
Crossref
Yusuke Okuma, Jumpei Kashima, Kageaki Watanabe & Sadamu Homma. (2018) Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Journal of Cancer Research and Clinical Oncology 144:8, pages 1601-1611.
Crossref
Crossref
Zhixin Sheng & Yanxia Zhang. (2017) The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor. American Journal of Clinical Oncology 40:4, pages 362-369.
Crossref
Crossref
XF Zhang, LV De-Sheng, M Li, GE Sun & CH Liu. (2017) A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia. Indian Journal of Cancer 54:1, pages 104.
Crossref
Crossref
Oscar Arrieta, Pablo Anaya, Vicente Morales-Oyarvide, Laura Alejandra Ram?rez-Tirado & Ana C. Polanco. (2015) Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin?paclitaxel. The European Journal of Health Economics 17:7, pages 855-863.
Crossref
Crossref
Mizue Hasegawa, Fumikazu Sakai, Rinako Ishikawa, Fumiko Kimura, Hironori Ishida & Kunihiko Kobayashi. (2016) CT Features of Epidermal Growth Factor Receptor?Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. Journal of Thoracic Oncology 11:6, pages 819-826.
Crossref
Crossref
Jin Liu, Zhixin Sheng, Yanxia Zhang & Guixin Li. (2015) RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials. Targeted Oncology 11:1, pages 49-58.
Crossref
Crossref
Guifang Li, Shunji Gao, Zhixin Sheng & Bin Li. (2016) The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. Chemotherapy 61:4, pages 179-189.
Crossref
Crossref
Hee Joung Kim, Seong Hui Kang, Hyun Woo Chung, Jong Sik Lee, Sun Jong Kim, Kwang Ha Yoo & Kye Young Lee. (2015) Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. Thoracic Cancer 6:5, pages 629-635.
Crossref
Crossref
Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida & Namiki Izumi. (2015) Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver International 35:5, pages 1581-1589.
Crossref
Crossref
Mauricio Burotto, Elisabet E. Manasanch, Julia Wilkerson & Tito Fojo. (2015) Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials. The Oncologist 20:4, pages 400-410.
Crossref
Crossref
ZHUN WANG, QIAN-BO HAN, JIA-LEI GU, XIN-MIN YU, XIAO-JIANG SUN, QING-REN LIN, JUN FANG, YUE-ZHEN WANG, YA-PING XU & WEI-MIN MAO. (2015) Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma. Oncology Letters 9:1, pages 257-261.
Crossref
Crossref
Zhixin Sheng & Yanxia Zhang. (2014) EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer. Medical Oncology 32:1.
Crossref
Crossref
Chao-Hua Chiu, Teh-Ying Chou, Chi-Lu Chiang & Chun-Ming Tsai. (2014) Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. Cancer Chemotherapy and Pharmacology 74:4, pages 661-665.
Crossref
Crossref
James Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, Myung-Ju Ahn, Vichien Srimuninnimit, Chia-Chi Lin, Dong-Wan Kim, Chun-Ming Tsai, Helen Barraclough, Sedat Altug, Mauro Orlando & Keunchil Park. (2014) First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. European Journal of Cancer 50:13, pages 2219-2230.
Crossref
Crossref
Ying-qiu Pan, Wei-wu Shi, Dan-ping Xu, Hui-hui Xu, Mei-ying Zhou & Wei-hua Yan. (2014) Associations Between Epidermal Growth Factor Receptor Gene Mutation and Serum Tumor Markers in Advanced Lung Adenocarcinomas: A Retrospective Study. Chinese Medical Sciences Journal 29:3, pages 156-161.
Crossref
Crossref
Nan-Jie Zhao, Zhao Sun, Yuzhou Wang, Xiaohong Ning, Ning Jia, Changting Meng & Yingyi Wang. (2014) Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Case-Control Study. Translational Oncology 7:4, pages 508-512.
Crossref
Crossref
Xiaoxiang Rong, Xiaoli Cai, Rong Li, Jinzhang Chen, Quanshi Wang, Changxuan You, Wenyun Wu, Chuanxin Liu, Junyi Zhang & Rongcheng Luo. (2014) Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma. Thoracic Cancer 5:4, pages 297-303.
Crossref
Crossref
Zhengbo Song & Yiping Zhang. (2014) Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. Journal of Clinical Neuroscience 21:4, pages 591-595.
Crossref
Crossref
Yasoo Sugiura, Etsuo Nemoto, Osamu Kawai, Yasuyuki Ohkubo, Hisae Fusegawa & Shizuka Kaseda. (2013) Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. SpringerPlus 2:1.
Crossref
Crossref
Alicia S. ChenDominic A. SolimandoJrJr & J. Aubrey Waddell. (2013) Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. Hospital Pharmacy 48:11, pages 905-911.
Crossref
Crossref
Zhengbo Song, Baochai Lin, Lan Shao & Yiping Zhang. (2013) Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. Journal of the Chinese Medical Association 76:9, pages 481-485.
Crossref
Crossref
Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, Li Zhang, Shucai Zhang, Dong Wang, Qiang Li, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Ying Cheng, Jifeng Feng, Helong Zhang, Yong Song, Yi-Long Wu, Nong Xu, Jianying Zhou, Rongcheng Luo, Chunxue Bai, Yening Jin, Wenchao Liu, Zhaohui Wei, Fenlai Tan, Yinxiang Wang, Lieming Ding, Hong Dai, Shunchang Jiao, Jie Wang, Li Liang, Weimin Zhang & Yan Sun. (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. The Lancet Oncology 14:10, pages 953-961.
Crossref
Crossref
Bin-Chi Liao, Chia-Chi Lin & James Chih-Hsin Yang. (2013) First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs 73:4, pages 357-369.
Crossref
Crossref
Seung Tae Kim, Jae Sook Sung, Uk Hyun Jo, Kyong Hwa Park, Sang Won Shin & Yeul Hong Kim. (2013) Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?. Medical Oncology 30:1.
Crossref
Crossref
Jin-Bing Pan, Yu-Hong Hou & Guo-Jun Zhang. (2013) Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients. Asian Pacific Journal of Cancer Prevention 14:2, pages 695-700.
Crossref
Crossref
Seung Tae Kim, Hae-Yun Jung, Jae Sook Sung, Uk Hyun Jo, Tomoaki Tanaka, Koichi Hagiwara, Kyong Hwa Park, Sang Won Shin, Jun Suk Kim & Yeul Hong Kim. (2013) Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?. American Journal of Clinical Oncology 36:1, pages 57-63.
Crossref
Crossref
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng & Caicun Zhou. (2012) Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials. International Journal of Cancer 131:5.
Crossref
Crossref
Cesare GridelliFortunato CiardielloCiro GalloRonald FeldCharles ButtsVittorio GebbiaPaolo MaioneFloriana MorgilloGiovenzio GenestretiAdolfo FavarettoNatasha LeighlRafal WierzbickiSaverio CinieriYasmin AlamSalvatore SienaGiampaolo TortoraRaffaella FellettiFerdinando RiccardiGianfranco MancusoAntonio RossiFlavia CantileMing-Sound TsaoMauro SaiegGilda da Cunha SantosMaria Carmela PiccirilloMassimo Di MaioAlessandro MorabitoFrancesco Perrone. (2012) First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology 30:24, pages 3002-3011.
Crossref
Crossref
Jin Hyun Park, Se-Hoon Lee, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Seok-Chul Yang, Young Whan Kim & Dae Seog Heo. (2012) EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77:2, pages 433-437.
Crossref
Crossref
F. Wang, L.D. Wang, B. Li & Z.X. Sheng. (2012) Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials. Clinical Oncology 24:6, pages 396-401.
Crossref
Crossref
King Pan Ng, Axel M Hillmer, Charles T H Chuah, Wen Chun Juan, Tun Kiat Ko, Audrey S M Teo, Pramila N Ariyaratne, Naoto Takahashi, Kenichi Sawada, Yao Fei, Sheila Soh, Wah Heng Lee, John W J Huang, John C AllenJrJr, Xing Yi Woo, Niranjan Nagarajan, Vikrant Kumar, Anbupalam Thalamuthu, Wan Ting Poh, Ai Leen Ang, Hae Tha Mya, Gee Fung How, Li Yi Yang, Liang Piu Koh, Balram Chowbay, Chia-Tien Chang, Veera S Nadarajan, Wee Joo Chng, Hein Than, Lay Cheng Lim, Yeow Tee Goh, Shenli Zhang, Dianne Poh, Patrick Tan, Ju-Ee Seet, Mei-Kim Ang, Noan-Minh Chau, Quan-Sing Ng, Daniel S W Tan, Manabu Soda, Kazutoshi Isobe, Markus M Nöthen, Tien Y Wong, Atif Shahab, Xiaoan Ruan, Valère Cacheux-Rataboul, Wing-Kin Sung, Eng Huat Tan, Yasushi Yatabe, Hiroyuki Mano, Ross A Soo, Tan Min Chin, Wan-Teck Lim, Yijun Ruan & S Tiong Ong. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine 18:4, pages 521-528.
Crossref
Crossref
Kwan-Ho LeeKye-Young LeeYoung-June JeonMaan-Hong JungChoonhee SonMin-Ki LeeJeong-Seon RyuSei-Hoon YangJae-Cheol LeeYoung-Chul KimSun-Young Kim. (2012) Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE). Tuberculosis and Respiratory Diseases 73:6, pages 303.
Crossref
Crossref
Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75:1, pages 82-88.
Crossref
Crossref
Taegyeong Kang, Hosub Lee, Dongcheol Choe, Sang-Woo Joo, So Yeong Lee, Kyong-Ah Yoon & Kangtaek Lee. (2012) Simultaneous detection of multiple mutations in epidermal growth factor receptor based on fluorescence quenching of quantum dots. Biosensors and Bioelectronics 31:1, pages 558-561.
Crossref
Crossref
A Horiike, K Kudo, E Miyauchi, F Ohyanagi, K Kasahara, T Horai & M Nishio. (2011) Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer 105:8, pages 1131-1136.
Crossref
Crossref
George Santis, Roger Angell, Guillermina Nickless, Alison Quinn, Amanda Herbert, Paul Cane, James Spicer, Ronan Breen, Emma McLean & Khalid Tobal. (2011) Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR. PLoS ONE 6:9, pages e25191.
Crossref
Crossref
Marco Platania, Francesco Agustoni, Barbara Formisano, Milena Vitali, Monika Ducceschi, Filippo Pietrantonio, Nicoletta Zilembo, Francesco Gelsomino, Sara Pusceddu & Roberto Buzzoni. (2011) Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology 6:3, pages 181-186.
Crossref
Crossref
Yosuke Togashi, Katsuhiro Masago, Takeshi Kubo, Yuichi Sakamori, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Tadashi Mio, Kaori Togashi & Michiaki Mishima. (2011) Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer 117:4, pages 819-825.
Crossref
Crossref
Hamid R Mirshahidi & Chung T Hsueh. (2010) Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. Journal of Hematology & Oncology 3:1.
Crossref
Crossref
Tony Mok, Yi-long Wu, Joseph Siu-kie Au, Caicun Zhou, Li Zhang, Reury-Perng Perng & Keunchil Park. (2010) Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, pages 1609-1615.
Crossref
Crossref
A D Roses, M W Lutz, H Amrine-Madsen, A M Saunders, D G Crenshaw, S S Sundseth, M J Huentelman, K A Welsh-Bohmer & E M Reiman. (2009) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. The Pharmacogenomics Journal 10:5, pages 375-384.
Crossref
Crossref
Yoichi Nakamura, Kazumi Sano, Hiroshi Soda, Hiroshi Takatani, Minoru Fukuda, Seiji Nagashima, Tomayoshi Hayashi, Mikio Oka, Kazuhiro Tsukamoto & Shigeru Kohno. (2010) Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, pages 1404-1409.
Crossref
Crossref
Fengsheng Chen, Xi Luo, Jinbiao Zhang, Yang Lu & Rongcheng Luo. (2009) Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology 27:3, pages 950-957.
Crossref
Crossref
Yun Jung Choi, Jin Kyung Rho, Byung-suk Jeon, Su Jin Choi, Su Cheol Park, Seung Sook Lee, Hye-Ryoun Kim, Cheol Hyeon Kim & Jae Cheol Lee. (2009) Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemotherapy and Pharmacology 66:2, pages 381-388.
Crossref
Crossref
Seung Tae Kim, Jeeyun Lee, Jeong‐hoon Kim, Young‐Woong Won, Jong‐Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park & Myung‐Ju Ahn. (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116:12, pages 3025-3033.
Crossref
Crossref
Tsuyoshi Takahashi, Makoto Sonobe, Masashi Kobayashi, Akihiko Yoshizawa, Toshi Menju, Ei Nakayama, Nobuya Mino, Shotaro Iwakiri, Kiyoshi Sato, Ryo Miyahara, Kenichi Okubo, Toshiaki Manabe & Hiroshi Date. (2009) Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene. Annals of Surgical Oncology 17:3, pages 889-897.
Crossref
Crossref
Shotaro Ide, Hiroshi Soda, Tomoaki Hakariya, Shinnosuke Takemoto, Hiroshi Ishimoto, Shinya Tomari, Toyomitsu Sawai, Seiji Nagashima, Masataka Furukawa, Yoichi Nakamura & Shigeru Kohno. (2010) Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event. Lung Cancer 67:2, pages 248-250.
Crossref
Crossref
Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour & Masahiro Fukuoka. (2009) Gefitinib or Carboplatin?Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine 361:10, pages 947-957.
Crossref
Crossref
Yoichi NaitoKoichi Goto. (2009) Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. Clinical Medicine. Therapeutics 1, pages CMT.S2122.
Crossref
Crossref
Se Hoon ParkSeung Yeon HaJae-Ik LeeHyewon LeeHoyong SimYoung Saing KimJunshik HongJinny ParkEun Kyung ChoDong Bok ShinJae Hoon Lee. (2009) Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung. Journal of Korean Medical Science 24:3, pages 448.
Crossref
Crossref
H. Jiang. (2008) Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective. Japanese Journal of Clinical Oncology 39:3, pages 137-150.
Crossref
Crossref
Chia-Hsuin Chang, Kuan-Yu Chen, Yinong Young-Xu, Tobias Kurth, E. John Orav, Pan-Chyr Yang & K. Arnold Chan. (2008) The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis. Lung Cancer 62:2, pages 242-252.
Crossref
Crossref
Purvish Parikh, Alex Yuang-Chi Chang, Shona Nag, Raghunadharao Digumarti, Gouri Shankar Bhattacharyya, Dinesh Chandra Doval, Govind Babu, Raju Titus Chacko, Suresh Advani, Anantbhushan Ranade, Shyam Aggarwal, Ramesh Jagannathan, Laura Hargreaves & Nick Thatcher. (2008) Clinical Experience with Gefitinib in Indian Patients. Journal of Thoracic Oncology 3:4, pages 380-385.
Crossref
Crossref
Runbo Zhong, Baohui Han & Bo Jin. (2008) Current research on consolidation therapy and follow-up health care in advanced non-small cell lung cancer patients. Chinese Journal of Clinical Oncology 5:2, pages 146-149.
Crossref
Crossref
Xiuhua Sun, Yang Zhang, Xian Zhang, Jing Yu, Yinghua Li, Xiaoyan Yang, Zhaoxia Dai & Man Li. (2008) The clinical evaluation of Iressa first-line treatment of senium advanced-stage non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 7:4, pages 203-206.
Crossref
Crossref
Silvio Garattini. (2008) Do Clinical Trials Always Benefit Patients?. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 13:2, pages 95-109.
Crossref
Crossref
Byoung Chul Cho, Chong-Kun Im, Moo-Suk Park, Se Kyu Kim, Joon Chang, Jong Pil Park, Hye Jin Choi, Yu Jin Kim, Sang-Joon Shin, Joo Hyuk Sohn, Hoguen Kim & Joo Hang Kim. (2007) Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib. Journal of Clinical Oncology 25:18, pages 2528-2533.
Crossref
Crossref
Alison ARMOUR. (2007) Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia-Pacific Journal of Clinical Oncology 3:2, pages 66-78.
Crossref
Crossref
Yi-Long Wu, Wen-Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin, Qing Zhou, Chong-Rui Xu, Zhen Wang, Guo-Chun Zhang & Tony Mok. (2007) Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology 2:5, pages 430-439.
Crossref
Crossref
Danan Li, Hongbin Ji, Sara Zaghlul, Kate McNamara, Mei-Chih Liang, Takeshi Shimamura, Shigeto Kubo, Masaya Takahashi, Lucian R. Chirieac, Robert F. Padera, Andrew M. Scott, Achim A. Jungbluth, Webster K. Cavenee, Lloyd J. Old, George D. Demetri & Kwok-Kin Wong. (2007) Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas. Journal of Clinical Investigation 117:2, pages 346-352.
Crossref
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:9.
Crossref
Crossref
Gary M. Clark, Denni M. Zborowski, Pedro Santab?rbara, Keyue Ding, Marlo Whitehead, Lesley Seymour & Frances A. Shepherd. (2006) Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non?Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clinical Lung Cancer 7:6, pages 389-394.
Crossref
Crossref